AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio to accelerate the future of AI drug discovery. Absci will deploy AMD high-performance compute and software to advance development of next-gen antibody therapeutics and transform creation of biologics for patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci, AMD announce collaboration, strategic investment
- Absci price target lowered to $5 from $6 at KeyBanc
- Absci, Invetx partner to bring AI drug creation platform to animal health
- Absci highlights progress, updates across proprietary pipeline
- Cathie Wood’s ARK Investment bought 202.6K shares of Absci today